Altimmune Shareholders Equity vs Interest Expense Analysis
ALT Stock | USD 7.04 0.48 6.38% |
Trend analysis of Altimmune balance sheet accounts such as Other Current Liab of 17.1 M, Total Current Liabilities of 21.2 M or Total Stockholder Equity of 203.8 M provides information on Altimmune's total assets, liabilities, and equity, which is the actual value of Altimmune to its prevalent stockholders. By breaking down trends over time using Altimmune balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Altimmune |
About Altimmune Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Altimmune at a specified time, usually calculated after every quarter, six months, or one year. Altimmune Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Altimmune and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Altimmune currently owns. An asset can also be divided into two categories, current and non-current.
Altimmune Balance Sheet Chart
Altimmune Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Altimmune uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Altimmune's Other Stockholder Equity is comparatively stable compared to the past year. Total Liabilities is likely to gain to about 27.3 M in 2024, whereas Accounts Payable is likely to drop slightly above 1.5 M in 2024. Add Fundamental
Total Assets
Total assets refers to the total amount of Altimmune assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Altimmune books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Altimmune balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Altimmune are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Altimmune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.At this time, Altimmune's Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 44.70 in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (5.31).
2021 | 2022 | 2023 | 2024 (projected) | Research Development | 74.5M | 70.5M | 65.3M | 68.6M | Depreciation And Amortization | 11.2M | 2.8M | 477K | 453.2K |
Altimmune fundamental ratios Correlations
Click cells to compare fundamentals
Altimmune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Altimmune fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 54.1M | 245.1M | 218.9M | 206.9M | 210.6M | 221.2M | |
Other Current Liab | 3.6M | 11.0M | 6.1M | 11.8M | 9.6M | 17.1M | |
Total Current Liabilities | 3.9M | 12.0M | 18.3M | 17.1M | 12.1M | 21.2M | |
Total Stockholder Equity | 45.5M | 225.9M | 199.1M | 185.3M | 194.1M | 203.8M | |
Net Debt | (7.2M) | (114.1M) | (188.8M) | (110.0M) | (134.5M) | (127.8M) | |
Retained Earnings | (137.4M) | (186.4M) | (293.2M) | (377.9M) | (466.3M) | (443.0M) | |
Accounts Payable | 18.2K | 612.3K | 2.0M | 4.8M | 2.1M | 1.5M | |
Cash | 9.0M | 115.9M | 190.3M | 111.1M | 135.2M | 141.9M | |
Cash And Short Term Investments | 37.2M | 215.9M | 190.3M | 184.9M | 197.9M | 207.7M | |
Common Stock Total Equity | 876.0 | 1.5K | 3.7K | 4.1K | 4.7K | 3.9K | |
Common Stock Shares Outstanding | 13.1M | 25.6M | 41.3M | 46.9M | 53.2M | 55.9M | |
Liabilities And Stockholders Equity | 54.1M | 245.1M | 218.9M | 206.9M | 210.6M | 221.2M | |
Other Current Assets | 504.4M | 2.0B | 13.4B | 5.4M | 6.8M | 6.5M | |
Other Stockholder Equity | 187.9M | 417.3M | 497.3M | 568.4M | 665.4M | 698.7M | |
Total Liab | 8.5M | 19.2M | 19.7M | 21.6M | 16.5M | 27.3M | |
Total Current Assets | 39.4M | 230.3M | 204.1M | 192.8M | 209.5M | 220.0M | |
Common Stock | 1.5K | 3.7K | 4.1K | 5K | 7K | 4.2K | |
Other Assets | 128.5K | 977.2K | 73.8K | 19K | 1.0 | 0.95 | |
Non Current Liabilities Total | 4.6M | 7.2M | 1.5M | 4.6M | 4.4M | 4.7M | |
Short Term Debt | 259.4K | 356.7K | 411.5K | 452K | 496K | 471.2K | |
Short Long Term Debt Total | 1.7M | 1.8M | 1.5M | 1.1M | 671K | 637.5K | |
Property Plant And Equipment Net | 1.8M | 2.0M | 1.4M | 1.1M | 1.0M | 1.5M | |
Non Current Assets Total | 14.7M | 14.9M | 14.7M | 14.1M | 1.1M | 1.1M | |
Non Currrent Assets Other | 128.5K | 73.4K | 872.0K | 615K | 100.0K | 95.0K | |
Net Receivables | 1.7M | 12.4M | 5.8M | 2.5M | 4.9M | 5.0M | |
Property Plant And Equipment Gross | 1.8M | 2.0M | 1.4M | 2.6M | 2.6M | 1.6M | |
Accumulated Other Comprehensive Income | (5.0M) | (5.0M) | (5.0M) | (5.2M) | (5.0M) | (4.8M) | |
Intangible Assets | 12.7M | 12.8M | 12.4M | 12.4M | 14.3M | 11.8M | |
Net Tangible Assets | 32.8M | 213.1M | 186.7M | 172.9M | 198.8M | 208.7M | |
Long Term Debt | 1.9M | 1.9M | 1.8M | 1.5M | 1.7M | 1.5M | |
Retained Earnings Total Equity | (116.9M) | (137.4M) | (186.4M) | (293.2M) | (337.1M) | (354.0M) | |
Capital Surpluse | 170.2M | 187.9M | 417.3M | 497.3M | 571.9M | 600.5M | |
Property Plant Equipment | 1.1M | 1.1M | 1.4M | 1.7M | 1.9M | 2.0M | |
Long Term Debt Total | 1.9M | 1.9M | 1.8M | 1.5M | 1.7M | 2.0M | |
Non Current Liabilities Other | 2.8M | 5.4M | 1.5M | 3.9M | 4.2M | 4.4M | |
Other Liab | 3.1M | 7.2M | 330.5K | 3.9M | 4.5M | 3.3M |
Altimmune Implied Volatility | 264.08 |
Altimmune's implied volatility exposes the market's sentiment of Altimmune stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Altimmune's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Altimmune stock will not fluctuate a lot when Altimmune's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Altimmune in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Altimmune's short interest history, or implied volatility extrapolated from Altimmune options trading.
Pair Trading with Altimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.Moving together with Altimmune Stock
0.73 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
0.68 | KZR | Kezar Life Sciences Financial Report 9th of May 2024 | PairCorr |
Moving against Altimmune Stock
0.46 | MRKR | Marker Therapeutics | PairCorr |
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Altimmune Stock analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Revenue Per Share 0.008 | Quarterly Revenue Growth 180 | Return On Assets (0.25) | Return On Equity (0.47) |
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.